June 30, 2026
Muna Therapeutics Announces CEO Transition as Clinical Pipeline Advances

COPENHAGEN, Denmark & BOSTON, June 30, 2026 – Muna Therapeutics (Muna), a biotechnology company pioneering novel therapeutics for neurodegenerative diseases, today announced a CEO transition. Rita Balice-Gordon, Ph.D., Muna’s founding CSO and CEO since 2021, will step down and join the Company’s Board of Directors. Michel Detheux, Ph.D., a seasoned biotech entrepreneur and former President and CEO of iTeos Therapeutics (NASDAQ: ITOS), has been appointed CEO, effective June 29, 2026.

Read More
June 4, 2026
Muna Therapeutics Announces Nature Medicine Publication Validating Microglial State Transitions as Key Drivers of Alzheimer’s

COPENHAGEN, Denmark and BOSTON, U.S., June 4, 2026 – Muna Therapeutics, a clinical-stage biotechnology company pioneering a new era of drug discovery for neurodegenerative diseases, today announced the publication of a seminal study in Nature Medicine: “Human microglial transitions at the Aβ–Tau inflection point associate with divergent pathways to dementia and resilience.”

Read More
January 8, 2026
Muna Therapeutics Awarded $1 Million Alzheimer's Association Grant to Advance Clinical Development of Novel Oral TREM2 Agonist MNA-001 for Alzheimer’s

COPENHAGEN, Denmark and BOSTON, U.S., January 8, 2026 – Muna Therapeutics, a clinical-stage biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, today announced it has been awarded a $1 million research grant from the Alzheimer’s Association to support its ongoing Phase 1 trial of MNA-001—a novel potent, selective and orally administered small molecule, in healthy young and elderly subjects—and its work to identify and validate translational biomarkers of the function and activation of triggering receptor expressed on myeloid cells 2 (TREM2) in the context of Alzheimer’s disease.

Read More